Received Apr 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 1 | — | — |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 2 | — | — |
No other AE/No PQC; who received their first dose of VAQTA 3 years ago and will be receiving their second dose today (31MAR2026); This spontaneous report was received from a pharmacist referring to an adult patient. The patient's pertinent medical history, known drug allergies or reactions, and concomitant therapies were not reported. On an unspecified date in 2023 (reported as 3 years ago), the patient was vaccinated with the first dose of hepatitis a vaccine, inactivated (VAQTA) injection (dose, route of administration, anatomical site, lot #, and expiration date were not reported). On 31-MAR-2026, the patient received the second dose of hepatitis a vaccine, inactivated (VAQTA) injection (dose, route of administration, anatomical site, lot #, and expiration date were not reported) (Inappropriate schedule of product administration). No adverse event. Lot # is being requested and will be submitted if received.